Abbott Laboratories trades at a premium multiple that reflects its high-quality, defensive profile and predictable cash generation. The company’s recurring revenue streams from established medical device platforms underpin management’s confidence in sustaining low-volatility earnings growth through 2027. Free cash flow conversion exceeded 85% in the most recent fiscal year, allowing for steady investment in R&D alongside capital returns to shareholders via dividends and share repurchases.

Within the Medical Devices division, Diabetes Care led expansion with over 12% segment growth in the latest quarter. The Libre continuous glucose monitoring system generated more than $2 billion in revenue, representing 17% year-over-year growth and capturing increased market share in Europe and North America. Other device franchises, including cardiovascular and neuromodulation, contributed mid-single-digit growth, demonstrating balanced portfolio momentum.

Management reaffirmed 2025 organic sales growth guidance of 7.5%–8.0% and earnings per share in the range of $5.12 to $5.18, underscoring the company’s resilient performance expectations. Operating margins are projected to expand by approximately 50 basis points as synergies from recent product introductions and manufacturing efficiencies take hold. Analysts estimate consistent annual EPS growth of 8%–10% through 2027, supported by ongoing innovation in both established and emerging therapeutic areas.